

Alberto Gabizon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2358217/publications.pdf>

Version: 2024-02-01

17
papers

2,744
citations

623574

14
h-index

940416

16
g-index

18
all docs

18
docs citations

18
times ranked

4412
citing authors

#	ARTICLE	IF	CITATIONS
1	Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy. , 2021, 4, 463-484.		4
2	A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer.. Journal of Clinical Oncology, 2021, 39, 1049-1049.	0.8	1
3	Development of Promitil [®] , a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside. Advanced Drug Delivery Reviews, 2020, 154-155, 13-26.	6.6	28
4	Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA). Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1407-1416.	1.7	61
5	Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy. Molecular Pharmaceutics, 2017, 14, 4339-4345.	2.3	18
6	Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer. Journal of Drug Targeting, 2016, 24, 878-889.	2.1	28
7	Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil [®]): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues. Pharmaceutical Research, 2016, 33, 686-700.	1.7	28
8	Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics". Journal of the National Cancer Institute, 2014, 106, dju321-dju321.	3.0	26
9	Adoptive Immunotherapy of Epithelial Ovarian Cancer with V β 13 γ 2 T Cells, Potentiated by Liposomal Alendronic Acid. Journal of Immunology, 2014, 193, 5557-5566.	0.4	43
10	Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. Kidney International, 2014, 85, 213.	2.6	12
11	Next-generation sequencing (NGS) in metastatic colorectal cancer (CRC) patients (pts) in Israel.. Journal of Clinical Oncology, 2014, 32, e14548-e14548.	0.8	0
12	Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: Studies with human gastro-entero-pancreatic ectopic tumor models. Journal of Controlled Release, 2012, 160, 245-253.	4.8	55
13	Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemotherapy and Pharmacology, 2010, 66, 43-52.	1.1	105
14	An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemotherapy and Pharmacology, 2008, 61, 695-702.	1.1	99
15	Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Advanced Drug Delivery Reviews, 2004, 56, 1177-1192.	6.6	434
16	Pharmacokinetics of Pegylated Liposomal Doxorubicin. Clinical Pharmacokinetics, 2003, 42, 419-436.	1.6	1,339
17	In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clinical Cancer Research, 2003, 9, 6551-9.	3.2	212